Back

SGLT2 inhibitor dapagliflozin attenuates cardiomyocyte injury and inflammation induced by PI3Kα-selective inhibitor alpelisib and fulvestrant under hyperglycemia

29 August 2026 (14:15 - 14:45)
Organised by: Logo
Congress Presentation Part of: Targeting inflammation in cardiovascular diseases and pre-clinical models Cardiotoxicity of Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

4 More presentations in this session

Presentation thumbnail
Comparative effectiveness of anti-inflammatory therapies for atherosclerotic cardiovascular disease: a systematic review and network meta-analysis of 16 randomised trials
Ms Y. Srivastava (IN)
Abstract
Presentation thumbnail
Temporal changes and treatment-associated stabilization of aortic ruptured plaques assessed by non-obstructive general angioscopy
Doctor K. Kojima (Tokyo, JP)
Abstract
Presentation thumbnail
Inflammation promotes extra-adrenal-ang II–independent aldosterone release by circulating immune cells in patients with coronary artery disease
Doctor A. Mroueh (Strasbourg, FR)
Abstract
Presentation thumbnail
Impact of inclisiran on the cardiometabolic–inflammatory index: a real-world observational study
Doctor Q. Zhang (Guangzhou, CN)
Abstract

Access the full session

Session thumbnail
Targeting inflammation in cardiovascular diseases and pre-clinical models

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
20 June 2025
thumbnail
Congress Presentation
The effect of one year treatment with GLP1-RA, SGLT2i and their combination on plasma levels of oxidative and antioxidative biomarkers
27 August 2021
thumbnail
Congress Presentation
Patient vascular model reveals anti-inflammatory effects of SGLT2 inhibitor by modulating endothelial-T cell crosstalk
31 August 2025
thumbnail
Congress Presentation
Myocardial ketone body oxidation underlies the salutary effects of SGLT2 inhibitor treatment in heart failure
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources